Allozymes Analysis
What is Allozymes?
Ultra-high-throughput enzyme discovery platform with 20M daily screenings and 7B data points
Employees
11-50
Founded
2020
HQ Full Address
Singapore, Singapore, Singapore
Product Features & Capabilities
- Ultra-high-throughput screening of 20M enzyme variants daily
- 7B data points generated annually
- ZymeLeap™ enzyme database with function-correlated sequences
- Enzyme Engineering Service for fast-track bioengineering
- Biosolutions License for sustainable product development
- Database Access for a fee
Investment Focus
Allozymes is targeting several primary market focus areas, including: - **Pharmaceuticals**: Developing enzymes for more efficient small molecule development and production. - **Life Sciences & Diagnostics**: Creating next-generation enzymes for various applications. - **Food & Nutrition**: Upcycling food companies' side streams into soluble fiber to combat diabetes and obesity. - **Chemical**: Developing bioprocesses to lessen environmental impact. - **Bioremediation**: Exploring enzymes for environmental cleanup. - **Personal Care**: Creating sustainable cosmetic ingredients.
Other Considerations
Prevents 6.4M liters of biohazard waste and 6,400 tons of plastic waste; Backed by XORA, SOSV, TI Platform, Entrepreneur First, Seventure, Thia Ventures, and NUS; Commercial partner with Adisseo (Bluestar Company)
Key Innovations
Allozymes has developed several key innovations and products in the biotech sector, including:
- A proprietary ultra-high-throughput microfluidics platform that enables the rapid development and screening of enzymes, analyzing over 20 million variants per day.
- Enzymes designed for efficient small molecule development in pharmaceuticals, promoting sustainability.
- Next-generation enzymes for life science and diagnostic applications, enhancing accuracy and scope.
- Proprietary enzymes that upcycle food companies' side streams into soluble fiber, addressing issues related to diabetes and obesity.
- Eco-friendly enzyme solutions for bioremediation and waste management.
- Aiming to build the world's largest enzyme data library to support sustainable industrial processes and democratize access to enzymatic solutions.
Latest Funding Round
Allozymes, a Singapore-based biotechnology company, raised $15 million in a Series A funding round. This funding was announced on May 15, 2024, and was led by Seventure Partners and Xora Innovation. The company aims to utilize this investment to enhance its enzyme discovery and engineering capabilities.
Awards Recognition
Allozymes has received several awards and recognitions in the biotech field, including:
1. The Future Food Asia Award, which they won in recognition of their innovative contributions to the food industry.
2. They were recognized for having the Most Innovative Service or Technology Supporting Food & Beverage for their proprietary enzyme engineering technology.
3. They were finalists for the Innovation Awards 2022.
1. The Future Food Asia Award, which they won in recognition of their innovative contributions to the food industry.
2. They were recognized for having the Most Innovative Service or Technology Supporting Food & Beverage for their proprietary enzyme engineering technology.
3. They were finalists for the Innovation Awards 2022.
Partnerships
- Collaboration with Bonumose - Announced on March 31, 2025, this partnership aims to accelerate enzyme innovations for beneficial food and supplement ingredients. [Source](https://fox4kc.com/business/press-releases/cision/20250331CN52337/allozymes-and-bonumose-collaborate-to-accelerate-enzyme-innovations-for-beneficial-food-supplement-ingredients/)
- Partnership with Adisseo
- Joint Venture with Syensqo
- Partnership with GenScript
- Membership in the Enzyme Technology Alliance - Allozymes was welcomed into this alliance, which includes various players in the enzyme technology space, announced on October 18, 2023. [Source](https://enzymicals.com/enzyme-technology-alliance-welcomes-allozymes-and-spinchem/)
Find more companies like Allozymes
Financial Overview
Allozymes, a Singapore-based biotechnology company, raised $15 million in a Series A funding round. This funding was announced on May 15, 2024, and was led by Seventure Partners and Xora Innovation. The company aims to utilize this investment to enhance its enzyme discovery and engineering capabilities.
